LabCorp
Mar 31, 2020
J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M
Johnson & Johnson is fast-forwarding its vaccine development program for COVID-19. The healthcare company has selected a lead vaccine candidate and is planning to begin human trials in September, with first batches available under potential emergency use authorization in the first part of 2021. The ...
Read More...
Feb 16, 2017
Reckitt Acquired Mead Johnson; LabCorp’s acquisition; Ferring collaborates; J&J Licenses
Mead Johnson Acquired By Reckitt Benckiser for $16.6 Billion Mead Johnson Nutrition Company (MJN), the manufacturer of infant formula and nutritional supplements, has agreed to be acquired by Britain's Reckitt Benckiser Group plc in a deal that values the former's equity at $16.6 billion. Mead Johnson shareholders w...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
